Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Recipient : AstraZeneca
Deal Size : Undisclosed
Deal Type : Termination
Circassia To Terminate AstraZeneca Deal And Transfer Assets
Details : On completion of the Transaction, AstraZeneca will acquire the U.S. commercial rights to Tudorza® and Duaklir® together with certain ancillary rights and assets, from Circassia.
Product Name : Eklira
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 04, 2020
Lead Product(s) : Aclidinium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Recipient : AstraZeneca
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2012
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
